<DOC>
	<DOCNO>NCT02239081</DOCNO>
	<brief_summary>This Phase 1 , single center , single-ascending dose , randomize study</brief_summary>
	<brief_title>A Safety Tolerability Study CTP-730 Healthy Volunteers</brief_title>
	<detailed_description>Following Screening period 21 day , eight ( 8 ) subject cohort , 6 subject randomize CTP-730 2 subject randomize placebo , admit clinical research unit ( CRU ) even dose remain sequester study site last inpatient blood sample collect 48 hour .</detailed_description>
	<criteria>Healthy male female volunteer subject , 18 50 year age , inclusive . Current significant medical condition , laboratory abnormality , psychiatric illness History clinically significant central nervous system ( eg , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal ( GI ) condition PR interval ≥ 220 msec QRS duration ≥ 120 msec QTcB / QTcF interval &gt; 450 msec Elevated liver function test great twice upper limit normal Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody Urinalysis positive protein glucose A positive screen alcohol , drug abuse , tobacco use . Inability comply food beverage restriction study participation Donation blood collection acute loss blood prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>